AMD’s spike reveals just how central CPUs are to the AI boom

Corning is spiking after Nvidia dropped $500 million for the right to buy up to 18 million of its shares.

The deal comes as part of a multiyear partnership that will see Corning “increase its U.S.-based optical connectivity manufacturing capacity by 10x and expand its U.S. fiber production capacity by more than 50% to meet the accelerating demand driven by AI factory buildouts,” per the press release.

The deal is structured around Corning issuing Nvidia two types of warrants:

• “Pre-funded” warrants for 3 million Corning shares (which account for the bulk of the $500 million to the fiber-optics company).

• “Traditional” warrants that enable Nvidia to buy 15 million shares at $180, thereby benefiting from Corning’s share price trading above that level within three years’ time (unless this partnership is terminated or Corning makes a “fundamental transaction” before that). If and when Nvidia exercises those warrants in full, CEO Jensen Huang will be cutting a much heftier check to Corning.

So while on the surface this deal may not look as big as Nvidia’s recent $2 billion investments in Marvell Technology, Coherent, and Lumentum, once all the dust settles, it could turn out to be considerably more!

AMC shares are rising in early Wednesday trading after the theater chain reported Q1 earnings results with revenue exceeding estimates after the bell Tuesday.

Key numbers:

• Revenue of $1.05 billion (compared to analyst estimates of $972.6 million).

• Adjusted EBITDA of $38.3 million (estimate: $7.7 million).

Attendance reached 30.7 million in the US and 16.9 million internationally, with improving demand thanks to recently released movies like “Project Hail Mary,” “The Super Mario Galaxy Movie,” and “Michael.”

A prolonged string of positive operating results like these will be needed to improve AMC’s balance sheet over time. AMC is still carrying around $4 billion in debt, which management is aiming to refinance and pay down over time.

“Refinancing has bought time to delever amid the stop-and-go box-office rebound as film supply is set to improve,” Bloomberg Intelligence analysts Kevin Near and Geetha Ranganathan wrote in the wake of this release. “AMC expects to close more underperforming theaters this year and hinted that positive free cash flow may hinge on a strong 2027 movie slate.”

Analysts at Benchmark upgraded the stock to “buy” from “hold” following these Q1 results.

Oscar Health is soaring in premarket trading after it reported earnings results that beat Wall Street expectations and reaffirmed its full-year guidance.

For the first three months of 2026, the company reported:

• Earnings per share of $2.07, compared to the $1.11 analysts polled by FactSet were expecting.

• Revenue of $4.65 billion, higher than the $4.5 billion that was penciled in.

• A medical cost ratio of 70.5%, lower than the 73.8% the Street was expecting. The company said this was because of a “disciplined pricing strategy, claims and risk adjustment seasonality from metal and new member mix, and favorable prior period reserve development.”

For the full year, Oscar reaffirmed the guidance it gave in February:

• Revenues between $18.7 billion and $19 billion, in line with the $18.8 billion analysts are expecting.

• Its medical cost ratio to sit between 82.4% and 83.4%, also in line with the 83.3% the Street is penciling in.

The company, like most health insurers, struggled last year amid rising medical costs. Oscar’s higher-than-expected profit was driven by a sharp drop in medical costs and increased premiums alongside higher enrollment.